Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?-Reference-Cited by-同舟云学术

Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

Published:2022-01 Issue: Volume:169 Page:103538
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Insa Amelia^ORCID,Martín-Martorell Paloma^ORCID,Di Liello Raimondo^ORCID,Fasano Morena,Martini Giulia^ORCID,Napolitano Stefania,Vicidomini Giovanni,Cappabianca Salvatore,Franco Renato,Morgillo Floriana,Della Corte Carminia Maria

Funder

Merck

Astellas Pharma US

Roche

AstraZeneca

Sanofi

Amgen

Ipsen

Pfizer

Bayer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference89 articles.

1. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis;Abu-Sbeih;J. Clin. Oncol.,2019

2. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression;Aguilar;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2019

3. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: the PROLUNG phase 2 randomized clinical trial;Arrieta;JAMA Oncol.,2020

5. STING: infection, inflammation and cancer;Barber;Nat. Rev. Immunol.,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study;Journal of Clinical Oncology;2024-08-20

2. CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer;Cell Reports Medicine;2024-04

3. Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer;BMC Complementary Medicine and Therapies;2024-02-01

4. Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival;Clinical & Translational Immunology;2024-01

5. Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy;Journal of Inflammation Research;2023-08